Clinical Trials · NCT00642421

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Name: Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 3Octreotide

Phase: Phase 3
Recruitment status: Terminated
Sponsor: Ambrilia Biopharma, Inc.
Enrollment: 40
Start date: Feb 2008
Locations: 10 sites, 6 countries
Primary endpoint: To assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.

View Octreotide compound reference